An in vitro osteosarcoma 3D microtissue model for drug development

Journal of Biotechnology

Volumn 189, Issue , 2014, Pages 129-135

  Rimann, Markus ^a   Laternser, Sandra ^a   Gvozdenovic, Ana ^b   Muff, Roman ^b   Fuchs, Bruno ^b   Kelm, Jens M ^c   Graf Hausner, Ursula ^a  

^a ZURICH UNIVERSITY OF APPLIED SCIENCES   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c InSphero AG   (Switzerland)

Author keywords

3D tissue model; Alternative to animal testing; Drug development; Osteosarcoma; Personalised medicine

Indexed keywords

3-D TISSUES; ANIMAL TESTING; DRUG DEVELOPMENT; OSTEOSARCOMA; PERSONALISED MEDICINES;

CISPLATIN; DOXORUBICIN; KI 67 ANTIGEN; PACLITAXEL; PEMETREXED; TAUROLIDINE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFICACY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MONOLAYER CULTURE; OSTEOSARCOMA; PRIMARY CELL; PROCEDURES CONCERNING CELLS; SAOS 2 CELL LINE; THREE DIMENSIONAL MICROTISSUE; CELL LINE, TUMOR; HUMANS; IN SITU NICK-END LABELING; IN VITRO TECHNIQUES; INDIVIDUALIZED MEDICINE; METHODS;

CELL LINE, TUMOR; HUMANS; IN SITU NICK-END LABELING; IN VITRO TECHNIQUES; INDIVIDUALIZED MEDICINE; OSTEOSARCOMA;

EID: 84908333633     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2014.09.005     Document Type: Article

References (30)

1. Adamski J., Price A., Dive C., Makin G. Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha. PLOS ONE 2013, 8:e65304.
2. Akeda K., Nishimura A., Satonaka H., Shintani K., Kusuzaki K., Matsumine A., Kasai Y., Masuda K., Uchida A. Three-dimensional alginate spheroid culture system of murine osteosarcoma. Oncol. Rep. 2009, 22:997-1003.
3. Ando T., Ichikawa J., Okamoto A., Tasaka K., Nakao A., Hamada Y. Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J. Orthop. Res. 2005, 23:964-969.
4. Arai K., Sakamoto R., Kubota D., Kondo T. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system. Proteomics 2013, 13:2351-2360.
5. Arlt M.J., Walters D.K., Banke I.J., Steinmann P., Puskas G.J., Bertz J., Rentsch K.M., Ehrensperger F., Born W., Fuchs B. The antineoplastic antibiotic taurolidine promotes lung and liver metastasis in two syngeneic osteosarcoma mouse models and exhibits severe liver toxicity. Int. J. Cancer 2012, 131:E804-E812.
6. Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Flege S., Helmke K., Kotz R., Salzer-Kuntschik M., Werner M., Winkelmann W., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 2002, 20:776-790.
7. Bodmer N., Walters D.K., Fuchs B. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines. Pediatr. Blood Cancer 2008, 50:905-908.
8. Botter S.M., Neri D., Fuchs B. Recent advances in osteosarcoma. Curr. Opin. Pharmacol. 2014, 16C:15-23.
9. Choi I.K., Strauss R., Richter M., Yun C.O., Lieber A. Strategies to increase drug penetration in solid tumors. Front. Oncol. 2013, 3:193.
10. Cukierman E., Bassi D.E. The mesenchymal tumor microenvironment: a drug-resistant niche. Cell Adhes. Migr. 2012, 6:285-296.
11. Dai X., Ma W., He X., Jha R.K. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med. Sci. Monit. 2011, 17:RA177-RA190.
12. Duffaud F., Egerer G., Ferrari S., Rassam H., Boecker U., Bui-Nguyen B. A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma. Eur. J. Cancer 2012, 48:564-570.
13. Gill J., Ahluwalia M.K., Geller D., Gorlick R. New targets and approaches in osteosarcoma. Pharmacol. Ther. 2013, 137:89-99.
14. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010, 148:3-15.
15. Indovina P., Rainaldi G., Santini M.T. Hypoxia increases adhesion and spreading of MG-63 three-dimensional tumor spheroids. Anticancer Res. 2008, 28:1013-1022.
16. Jacobi C.A., Menenakos C., Braumann C. Taurolidine - a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 2005, 16:917-921.
17. Jaffe N. Osteogenic sarcoma: state of the art with high-dose methotrexate treatment. Clin. Orthop. Relat. Res. 1976, 95-102.
18. Kelm J.M., Fussenegger M. Microscale tissue engineering using gravity-enforced cell assembly. Trends Biotechnol. 2004, 22:195-202.
19. Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 2007, 1:84-96.
20. Liu B., Ma W., Jha R.K., Gurung K. Cancer stem cells in osteosarcoma: recent progress and perspective. Acta Oncol. 2011, 50:1142-1150.
21. Mohseny A.B., Hogendoorn P.C., Cleton-Jansen A.M. Osteosarcoma models: from cell lines to zebrafish. Sarcoma 2012, 417271.
22. Neary P.M., Hallihan P., Wang J.H., Pfirrmann R.W., Bouchier-Hayes D.J., Redmond H.P. The evolving role of taurolidine in cancer therapy. Ann. Surg. Oncol. 2010, 17:1135-1143.
23. Pampaloni F., Ansari N., Stelzer E.H. High-resolution deep imaging of live cellular spheroids with light-sheet-based fluorescence microscopy. Cell Tissue Res. 2013, 352:161-177.
24. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J. Rare Dis. 2007, 2:6.
25. Rimann M., Graf-Hausner U. Synthetic 3D multicellular systems for drug development. Curr. Opin. Biotechnol. 2012, 23:803-809.
26. Ritter J., Bielack S.S. Osteosarcoma. Ann. Oncol. 2010, 21(Suppl. 7):vii320-vii325.
27. Rodriguez-Enriquez S., Gallardo-Perez J.C., Aviles-Salas A., Marin-Hernandez A., Carreno-Fuentes L., Maldonado-Lagunas V., Moreno-Sanchez R. Energy metabolism transition in multi-cellular human tumor spheroids. J. Cell Physiol. 2008, 216:189-197.
28. Sampson V.B., Kamara D.F., Kolb E.A. Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery. Expert Opin. Drug Discov. 2013, 8:1181-1189.
29. Ta H.T., Dass C.R., Choong P.F., Dunstan D.E. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009, 28:247-263.
30. Walters D.K., Muff R., Langsam B., Gruber P., Born W., Fuchs B. Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Investig. New Drugs 2007, 25:305-312.